Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Alwan H, Ribero VA, Efthimiou O, Del Giovane C, Rodondi N, Duntas L
As we stand on the cusp of breakthroughs in obesity treatment, GLP-1 agonists appear poised to play a significant role in shaping the future landscape of weight management strategies
The mechanism: cortisol primes adipocytes for lipolysis by upregulating -AR density and downregulating alpha-2 adrenergic receptors (which inhibit fat release)
Long-term nutritional concerns also deserve attention
Studies and clinical trials show that when people stop taking GLP-1s, the appetite often comes back, and in many cases there is rapid weight regain, especially if nutrition and behavior changes werent made when on the medication, she says
Although the FDA has reported that several different dosages of semaglutide (aka Ozempic and Wegovy) are still in limited supply, Novo Nordisk CEO Lars Jrgensen told Forbes that his company has ramped up manufacturing. The company is now putting more starter doses the first patients receive until their doctors find the best dose level for them into the supply chain than it had initially projected for 2024
